Introduction
Among 6000 known hereditary syndromes, more than 700 involve dental or craniofacial defects. 1 Congenital and acquired craniofacial malformations resulting from impaired growth of the mandibles, such as micrognathia, and hemifacial microsomia are commonly found and require dental, speech, medical, behavioral and extraordinary surgical interventions. Surgical approaches include distraction osteogenesis, orthoganthic surgery and bone grafting. These approaches have limitations such as bone graft resorption, donor site morbidity, antigenicity potential and disease transmission. Although these traditional strategies had significant impact on bone regeneration, it is clear that their limitations leave an urgent need to explore alternative bone formation approaches. 2, 3 Moreover, most of the knowledge on the regulation of cartilaginous growth is derived from studies on growth plates of long bones; however, growth regulation of the secondary cartilage of mandibular condyle is unique and requires further investigation. 4 Osteogenesis and angiogenesis are closely correlated. 5 VEGF, the best-characterized angiogenic mediator, has been shown to play a critical role in long bone and mandibular condylar growth. 6, 7 Chondrocytes of the mandibular condyle express VEGF, which stimulates neovascularization and marks the onset of endochondral ossification. The perivascular connective tissues that surround the invading blood vessels are repository sites of mesenchymal cells. 8, 9 As such, these invading blood vessels will replenish the population size of mesenchymal cells and thus offer a bigger pool of osteoprogenitor cells. Loss of function by blocking VEGF with Flt-(1-3)-IgG administration or conditional inactivation of VEGF-A using Collagen2a1-Cre transgenic lines leads to aberrant endochondral bone formation, lack of normal blood vessel development and impairment of cartilage resorption. 6, 10 Some successful gain of function studies with recombinant VEGF proteins or gene encoding for the proteins a yielded significant increase in vascularization and bone regeneration in defects. 11, 12 However, it remains unknown whether exogenous VEGF can further enhance the growth of the specific organ -mandibular condyle. Resolving this issue is essential to develop a better delivery vehicle to introduce the gene of interest into the mandibular condyle. The advance of virus research has brought rAAV into the limelight of viral gene therapy. The rAAV vectors have considerable promise to overcome limitations of other delivery systems. They are now emerging as less pathogenic vectors, have the potential for long-term transgene expression, less pathogenicity, low immunogenicity, and the ability to infect a wide variety of dividing and nondividing cells. 2 It would be of great interest to determine if rAAV mediated VEGF gene delivery will present an alternative choice for enhancing the growth of the mandibular condyle.
Therefore, the purpose of this study is to assess expression and biological activity of the 164-isoform of VEGF-A mediated by rAAV in the mandibular condyle of Sprague-Dawley (SD) rats. This application also provides a better understanding of the regulation mechanism of mandibular condylar growth; hence it will be exploited to develop more effective treatment strategies to regulate condylar growth in future clinical practice.
Results

In vitro detection of transgene expression
To investigate the transduction efficiency, rAAV-2 vector expressing eGFP was used to infect the primary chondrocytes at a multiplicity of infection (MOI) of 5 Â 10 4 . Flow cytometric analysis showed that transduction rates are 49.3274.15% on day 3 and 72.4172.10% on day 5 ( Figure 1a ). Furthermore, we tested whether the encoded VEGF could be secreted into the medium. As shown in Figure 1b , the rAAV-VEGF-infected primary chondrocytes exhibited a significantly higher level of VEGF protein secretion than the rAAV-eGFP-transduced cells. The peak value of 30.3771.39 ng/ml was present at 72 h in the culture media of rAAV-VEGF-transduced primary chondrocytes. Therefore, rat chondrocytes could be transduced by rAAV-2 and transduction of the VEGF gene significantly elevated the secretion of VEGF.
In vivo detection of transgene distribution
The rAAV-VEGF injection into the temporo-mandibular joint (TMJ) posterior attachment resulted in transgene expression in cells located within the posterior attachment of condyle and condylar cartilage (Figure 2a1-a3) . Specially, chondroblasts, hypertrophic chondrocytes and some osteoblasts in the erosive zone also showed positive staining. However, lack of woodchuck hepatitis post-transcriptional regulatory element (WPRE) expression was identified in the phosphate-buffered saline (PBS)-injected animals ( Figure 2b ). This transgene expression was detected as early as day 7 and lasted for at least 60 days. These results suggest that rAAV successfully infected and stably transferred the exogenous gene to condylar cartilage of growing rats. Immunohistochemical studies confirmed increased VEGF protein expression in rAAV-VEGF delivered condyle, and the positive signal was detected in nearly all of the layers of condyle at day 30 post-injection (Figure 2c1 and c2) . However, the VEGF expression was limited to the hypertrophic layer in the control groups (Figure 2d1 and d2) . Quantified by Western blot analysis, on days 21, 30 and 60, in the experimental group, VEGF expression was 2.84-, 3.37-and 4.19-fold more than in the control group injected with rAAV-eGFP, respectively (Figure 2e1 and e2) .
Expression of exogenous VEGF in the mandibular joint and remote organs
After injection of rAAV-VEGF, rAAV-eGFP and PBS, total RNA was extracted from the right condyle and selected organs at different time intervals, and RT-PCR was conducted. As shown in Figure 3a , expression of VEGF mRNA was detected in condylar cartilage tissues as early as day 7 and, reaching the maximum level at 21 days, the expression lasted the whole experimental period of 60 days, which was consistent with the result of in situ hybridization. The exogenous gene expression was not detected in the joints of rAAV-eGFP or PBS-injected animals ( Figure 3b ). Moreover, in the remote organs of liver, kidney, heart and spleen of rAAV-VEGF-injected animals, mRNA expression of exogenous VEGF was not detected, thereby reducing the prospects of systemic adverse effects (Figure 3b ).
Circulating serum and bone level of VEGF
Using enzyme-linked immunosorbent assay (ELISA), the VEGF concentrations in rat serum and bone extracts among experimental and control groups were measured (Figure 3c) . Although the serum level of the rAAV-VEGF delivered group was higher than those two control groups from day 21 to day 60, no significant differences of serum VEGF levels were detected among all groups (P40.05). Even though the results show statistical insignificance, it might have clinical significance due to the duration of expression. However, in the experimental group, VEGF expressed on the basis of extractable protein from the mandibular condyle was significantly increased from day 14 and lasted during the whole time periods (Figure 3d ). On day 30, VEGF expression was 2.80-fold more than that in the control group. Comparing the VEGF secretion level in serum and bone extract, it reconfirmed that VEGF local injection of rAAV-VEGF increased the level of VEGF in the specified position and has less effect on the systemic level.
Morphological analysis
The length (A-B) and width (C-D) of the condylar head increased significantly from day 30 to day 60 ( Figure 4a , Table 1 ). Moreover, the length of the condylar process (G-F) significantly increased from day 30 to day 60 ( Figure 4b , Table 1 ). On days 7, 14 and 21, all VEGF induces mandibular condylar growth ABM Rabie et al the measured morphological parameters of the rats mandibles showed no significant difference among rAAV-VEGF delivery, rAAV-eGFP and PBS-injected group.
Expression of collagen type II, collagen type X, PCNA and TRAP activity Collagen type II, the major component of the cartilage, was positive in the chondroblast and hypertrophic layer, indicating the aggregation of extracellular matrix and maturation of the chondrocytes. When mature, spherical chondrocytes enlarge and secrete type X collagen, marking the onset of endochondral ossification in the lower hypertrophic layer. In the control groups, the collagen type II and type X positive layer decreased with age. However, after rAAV-VEGF delivery, the collagen type II positive layer was significantly increased at After rAAV-VEGF injection, the collagen type X positive layer had a similar pattern as collagen type II, reaching the maximum value at day 21, and abruptly decreased at day 30 ( Figure 5b ). Proliferating cell nuclear antigen (PCNA), a marker for cell proliferation, serves as an auxiliary protein of DNA polymerase a (Pol a), which is the principal enzyme responsible for the replication of chromosomal DNA. 13 In the VEGF-delivered group, the number of PCNA-positive cells in the proliferative layer increased from day 7 and the maximum proliferative index was 0.74670.038 on day 30; however, in rAAV-eGFP injection and PBS injection group, the proliferation index is 0.29370.022 and 0.30470.033, respectively (Figure 5c ). Tartrate-resistant acid phosphatase (TRAP) staining in the subchondral layer revealed numerous mono-and multinucleated TRAP-positive cells that were found attached to the bone at resorption lacunae. At day 30 post-injection, more active TRAPpositive chondroclasts were detected in the erosive zone in the rAAV-VEGF delivered group than that in control groups (Figure 5d ).
Biochemical analysis of ALP activity and osteocalcin content in bone extract
To quantify osteogenic responses, biochemical parameters such as the alkaline phosphatase (ALP) activity and osteocalcin content of mandibular condyle were analyzed at days 7, 14, 21, 30 and 60. ALP activity expressed on the basis of total protein was significantly increased by days 21 and 30, which were 2.78-and 5.41-fold increases when compared with that in rAAV-eGFPtreated control, respectively (Figure 6a ). The osteocalcin content was also significantly higher in the experimental group than in the control group with 2.54-and 1.34-fold changes on days 30 and 60, respectively (Figure 6b ).
Discussion
In the present study, we carried out successful transduction of rAAV-VEGF into rat condylar chondrocytes and showed expression in the deep layers of the condyles (Figure 2a ). The rAAV vector (22-25 nm in size) was small enough to diffuse from the injected joint space to the cell surface layers, and then deeper to infect chondrocytes and hypertrophic chondrocytes, and made them secrete the growth factor, VEGF. As a consequence, high levels of VEGF protein were readily detectable at the site of administration for at least 60 days after a single injection. More importantly, the expression of transgenes was condyle-specific, with RT-PCR revealing that RNA transcripts in hearts, kidneys, livers and spleens after viral transduction remained undetectable (Figure 3b ). It is also worthy to note that the virus was detected by in situ hybridization for WPRE in the glenoid fossa immediately adjacent to the site of injection. The virus was injected in the posterior attachment fibers connecting the posterior of the condyle and inserting the glenoid fossa. The absence of the virus from the distant organs and its presence in the condyles and glenoid fossa indicates that the virus spread by direct diffusion and not through the circulation. Therefore, rAAV-mediated gene delivery restricts transgene expression to defined anatomical locations.
Another important aspect in this study is the choice of VEGF as a good candidate for condylar growth. VEGF is a potent angiogenic peptide with specific mitogenic and chemotactic action on endothelial cells and is also an essential coordinator of chondrocyte death, chondroclast function, extracellular matrix remodeling, angiogenesis and bone formation in growth plate. 6 Recently, in vivo gene therapy with adenoviral VEGF-A was proved to be able to modify bone defect healing in rat femur.
12 Using the rabbit model, similar results were achieved where it was concluded that VEGF-A gene transfer induces bone formation via increasing osteoblast activity.
14 Moreover, allograft coated with a combination of rAAV-RANKL (receptor activator of NF-kB ligand) and rAAV-VEGF showed a marked increase in bone formation in a mouse femoral graft in vivo model. 15 The work discussed above lends credence to the role of VEGF in bone growth. In this study, we carried out a morphometric analysis and demonstrated a significant increase in the size of condylar head (12.3%), condylar width (10.6%) and the length of condylar process (8.0%) by rAAV-VEGF delivery on day 60. Biochemical analysis also presented a significant increase in ALP activity and osteocalcin VEGF induces mandibular condylar growth ABM Rabie et al content in the rAAV-VEGF-treated mandibular condyle from day 30. In contrast, by conditionally inactivating VEGF specifically in the cartilage using Collagen2a1-Cre transgenic mouse, the E17.5 embryos exhibited aberrant endochondral bone formation. 10 An interesting finding in this study was that VEGF expression by rAAV-VEGF delivery was localized nearly with whole layers of condyle (Figure 2a1-a3) . However, during natural growth as well as during induced condylar growth, VEGF was only expressed by hypertrophic chondrocytes. 9, 16, 17 By means of RT-PCR, immunostaining and Western blot, VEGF expression in the rAAV-VEGF delivered group reached a peak on day 21 (Figures 2e and 3a) , which is in agreement with previous reports that the maximal VEGF expression preceded the peak of new bone formation. 7 We also demonstrated that VEGF 164 gene delivery significantly increased the proliferation index of mesenchymal cells in the proliferative layer from day 7 (Figure 5c ). The population size of these proliferative mesenchymal cells directly impacts the growth of the condyles as it offers a bigger pool of cells to enter into the chondrogenic route and eventually engage in cartilage synthesis. 8 Cartilage is the template onto which bone will form and it greatly impacts condylar growth. Furthermore, VEGF signal was detected in the chondrocyte layer ( Figure 2a2 ) and its release into the extracellular matrix has been shown to be involved in the regulation of new blood vessel invasion into the hypertrophic chondrocytes and thus marks the onset of endochondral ossification of the condyle. 7 In a previous study, using the VEGF120/120 mice model, it was found that VEGF 164 and/or VEGF 188 are important not only in mediating vascularization but also in normal differentiation of progenitors to hypertrophic chondrocytes, osteoblasts, endothelial cells and osteoclasts. 18 VEGF here plays multiple roles; in addition to being a major angiogenic mediator in the condyle, it indirectly influences the differentiation of the mesenchymal cells at the erosive zone to enter the osteogenic route through the release of cytokines. Wang et al. 19 reported that VEGF indirectly induces proliferation and differentiation of osteoblasts by stimulating endothelial cells to produce osteoanabolic growth factors. In Decker et al's research, VEGF was expressed at low level at the beginning of osteoblast differentiation before bone sialoprotein and osteocalcin mRNA expression. During terminal differentiation of osteoblasts, their expression is strongly increased and achieves the maximum level at the period of mineralization, suggesting that VEGFs play an important role in the regulation of bone remodeling by stimulating osteoblast differentiation. 20 Peng et al. 21 recently reported that endogenous VEGF activity is one of the main mediators of angiogenesis during BMP2-induced bone formation. VEGF function appears to be critical not only for increased new bone formation but also for rapid cartilage resorption. The degradation of the cartilaginous matrix regulates vascular invasion mainly via the release of VEGF. 21 In our study, the hypertrophic zones identified by collagen type X staining in the VEGF delivery group were thinner than those of controls on day 30 (Figure 5b ). This finding is supported by the administration of soluble VEGF receptor 1 (sFlt1) to inhibit bone formation by delaying chondrocyte apoptosis and cartilage resorption, leading to a massive expansion in the thickness of VEGF induces mandibular condylar growth ABM Rabie et al the layer of hypertrophic chondrocytes. 6 It is worth noting that more active TRAP signal was detected in the rAAV2/2-VEGF delivered group than in control groups on day 30 (Figure 5d ). Peng's study also indicated that exogenous VEGF enhanced BMP2-or BMP4-elicited endochondral bone formation mainly by accelerating cartilage resorption. 21, 22 More recently, Blumer et al.
23
investigated that the growth of cartilage canals into the secondary ossification center was promoted by VEGF. The canals, an extension of the vascularized perichondrium, contained chondroclasts, which opened the lacunae of hypertrophic chondrocytes, and this was followed by invasion of mesenchymal cells into the empty lacunae and formation of an osteoid layer. The accelerated cartilage resorption was most likely the result of new blood vessel invasion, which can lead to the recruitment of chondroclasts to the area of bone formation. Meanwhile, increased angiogenesis may also have contributed to an increased number of osteoprogenitor cells, which can participate in bone formation. These two processes may act together to enhance bone formation. 21, 22 This suggests that VEGF-dependent new blood vessel recruitment is essential for coupling cartilage resorption and mineralized bone formation during endochondral ossification in bone development. 18, 21 Collectively, these results indicate that local rAAVmediated gene transfer of VEGF enhances mandibular condylar growth. The delivered VEGF enhances the population size of mesenchymal cells in the proliferative layer and increases chondrocyte proliferation and maturation. Its expression by hypertrophic chondrocytes and its release into the erosive zone induces the recruitment of osteoblasts and chondroclasts.
Materials and methods
Construction of rAAV-VEGF 164 and rAAV-eGFP vector
The full-length VEGF164 cDNA fragments were amplified by means of RT-PCR from total RNA of rat liver, using the following primers: VEGF induces mandibular condylar growth ABM Rabie et al was subcloned at the XhoI and EcoRI sites of the rAAV-2 expression vector. 24 Recombinant AAV vector encoding enhanced green fluorescent protein (rAAV-eGFP) was constructed with the same restriction enzyme sites. The integrity of cDNA constructs was confirmed by DNA sequence analysis.
Generation of rAAV-VEGF 164 and rAAV-eGFP Particles
Recombinant AAV particles were generated by a threeplasmid, helper-virus free packaging method with slight modification. 24 The rAAV expression constructs and the helper plasmids pFd6 and pH22 were transfected into HEK293 cells by calcium phosphate precipitation. The rAAV particles were purified by heparin affinity column chromatography. An aliquot was subjected to quantitative real-time PCR (qRT-PCR) analysis (Applied Biosystems, Foster City, CA, USA) to quantify the genomic viral titer.
In vitro expression of VEGF and eGFP
Primary rat chondrocytes were obtained from mandibular condylar cartilage removed under sterile conditions. According to the procedure by Dai et al., 25 the chondrocytes in passage 2 were chosen to culture in the complete Dulbecco's modified Eagle's medium (DMEM) and allowed to adhere for at least 24 h before addition of adeno-associated virus. The cells were washed once with PBS, and then the virions were added at the indicated number of 5 Â 10 4 (MOI) in culture medium supplemented as described above but with only 2% fetal bovine serum medium (FBS). After 5 h, cells were incubated in DMEM medium with 10% FBS. The capacity of rAAVeGFP infection on primary chondrocytes was analyzed by fluorescence microscopy and the transduction efficiency was performed by a FACSCalibur (BD), and expressed as the mean of four independent experiments. The culture media of the chondrocytes transduced with rAAV2/2-VEGF were collected and the VEGF concentration in the conditioned media was evaluated by ELISA.
Local injection of rAAV-VEGF 164 and rAAV-eGFP into rat condyle posterior attachment Ninety 35-day-old female SD rats were obtained from the Animal Units of the University of Hong Kong. All surgical procedures and care administered to the animals were approved by the University Ethics Committee and performed according to institutional guidelines. These SD rats were randomly allotted into one experimental group and two control groups. Injection procedure was performed as described previously. 25, 26 The 50 ml volume of rAAV-VEGF (2 Â l0 11 , genome copies), rAAV-eGFP (2 Â l0 11 , genome copies) or PBS was slowly injected directly into the posterior attachment of the rat condyle. Six rats from each subgroup were killed at days 7, 14, 21, 30 and 60 post-injection by an intraperitoneal injection of Dorminal. After death, the heads of these SD rats were skinned and, dissected into two halves. The right halves of the mandible were cleaned off the adherent connective tissues and snap-stored in liquid nitrogen for further RT-PCR, Western blot, ELISA and ALP activity analysis. The left halves were fixed to carry out morphological analysis and later embedded for in situ hybridization, histological and immunohistochemical staining.
In situ hybridization
The procedure was carried out as described previously. 27 Briefly, hybridization was performed with digoxigenin-11-UTP-labelled hybridizing (antisense) and non-hybridizing (sense) RNA probes transcribed from WPRE cDNA (a woodchuck posttranscriptional regulatory element, 600 bp) subcloned in pBluescript streptokinase (SK)(+) (Stratagene) plasmid by T3 or T7 RNA polymerases as protocols of in vitro transcription using a DIG RNA labelling kit (Roche Diagnostics Corp., Indianapolis, IN, USA). Hybridization was carried out at 601C for 16 h in a humidified chamber. Samples were then incubated 2 h with 2.5 U/ml ALP-conjugated anti-digoxigenin Fab fragments (Roche Diagnostics) and developed with NBT/BCIP solution (Roche Diagnostics). Specimens were finally treated with 0.02% methylgreen as counterstaining. Rat condyle sections were treated with PBS as controls.
RT-PCR
Mandibular condyle, liver, kidney, spleen and heart were harvested. Specially, the condylar cartilage was homogenized with Mikro-dismembrator U (Braun Biotech International GmbH, Melsungen, Germany). Immediately after total RNA was isolated from each organ by means of an RNeasy Fibrous Tissue Mini Kit (Qiagen Sciences, Maryland, MD, USA), the isolated total RNA of each sample was reverse transcribed using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen Corp., Carlsbad, CA, USA) following the manufacturer's instructions. Primers used for VEGF mRNA were forward 5 0 -CGGTCTCGAGATGAACTTTCT GCTCTCT-3 0 and reverse 5 0 -GTTCCGCCGTGGCAAT AG-3 0 (GenBank accession number NM031836) and VEGF induces mandibular condylar growth ABM Rabie et al GAPDH mRNA were forward 5 0 -ACCACAGTCCATGC CATCAC-3 0 and reverse 5 0 -TCCACCACCCTGTTGCTG TA-3 0 (GenBank accession number XM237330). The integrated optical densities of the resulting bands were collected and analyzed by Quality One (Bio-Rad Laboratories GmbH, Munich, Germany). The values for the bands were normalized to their corresponding GAPDH values and reported as fold change.
Morphological measurement
Gross morphological analysis was carried out as described in detail previously. 28 Digital pictures of the lateral view of the left mandible were obtained to allow for the linear measurements. Representative parameters of condylar growth were selected. Those images were amplified twice and were traced with selected landmarks and distance (Figure 4 ).
ELISA analysis
Quantification of rAAV-mediated VEGF expression in rat sera and condylar cartilage lysate was performed by a mouse VEGF ELISA kit (R&D Systems Inc., Minneapolis, MN, USA) following the manufacturer's instructions. Specially, the condylar cartilage was homogenized with Mikro-dismembrator U (Braun Biotech International). These experiments were repeated three times.
Biochemical analysis
To evaluate bone formation, the intracellular ALP and bone osteocalcin content were determined from condyle extracts. The mandibular condyles were weighed, homogenized and treated with RPMI lysis buffer with proteinase inhibitor at 41C for 10 min. The lysates were centrifuged at 14 000 r.p.m. for 10 min. The supernatants were used to determine the total protein by a BCA protein assay kit (Pierce Biotechnology Inc., Rockford, IL, USA). ALP activity was measured by incubation in tris buffer containing p-nitrophenylphosphate (pNPP) (Sigma) for 30 min at 371C. One unit was defined as the amount of enzyme that hydrolyzed 1 mmol pNPP/ minute. Enzyme activity was expressed as U/ml/mg protein. Osteocalcin was extracted from the sediment with 20% formic acid over a period of 3 days at 41C. The extract was desalted with a Sephadex G-25 column, and protein fractions were used to determine the concentration of osteocalcin with a Rat Osteocalcin EIA Kit (Biomedical Technologies Inc., Stoughton, MA, USA) following the manufacturer's instructions. 29 
Histological and immunohistochemical staining
To identify the activity of osteoclasts and chondroclasts, the characteristic of TRAP staining was identified with the Leukocyte Acid Phosphatase Kit (Sigma-Aldrich Corp., St Louis, MO, USA) following the manufacturer's instructions. 27 To test the expression of VEGF, collagen type II, collagen type X and PCNA a standard three-step avidin-biotin complex immunohistochemical staining was carried out as described previously. 27 The primary antibody for VEGF was a polyclonal goat IgG (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) for PCNA was a monoclonal mouse IgG (Santa Cruz Biotechnology) and for collagen type II was a polyclonal goat IgG (Santa Cruz Biotechnology). The primary antibody for type X collagen was a monoclonal mouse IgG (Quartett, Berlin, Germany). Control slides treated with non-immune serum instead of primary antibody were also processed. Image analysis was conducted via a computer-assisted image analyzing system (Leica DC 300 V 2.0) with software (Qwin V 2.4). A three-channel red-green-blue (RGB) color video camera was connected to a microscope (Leitz Orthoplan). Measurements were carried out in superior-posterior region of condyle as previously reported. 8, 30 Western blot Condylar cartilage protein samples were pooled from three animals of each group. For each of the blots, 30-50 mg of each protein pool was fractionated by 12% SDS-PAGE and transferred to Hybond PVDF membrane (Amersham Biosciences, Piscataway, NJ, USA). Polyclonal antibodies for VEGF (Santa Cruz) and Actin (Sigma) were used in conjunction with horseradish peroxidaseconjugated secondary antibodies and the Amersham biotech ECL Detection Kit (AB). The films were developed, digitally scanned, and the integrated optical density of the resulting bands were collected and analyzed by Quality One (Bio-Rad). The values for the bands were normalized to their corresponding actin values and reported as fold change.
Statistics
Statistical analysis was processed with SPSS for Windows (Release 11.0, standard version, LEAD Technologies Inc.) for one-way ANOVA with the Bonferroni multiple comparisons test to compare the mean difference among the experimental group and two control groups at each time point. P-values were considered to be statistically significant when less than 0.05.
